JPRN-UMIN000004055已完成2 期
Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer - Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for AGC
Aichi Cancer Center Hospital0 个研究点目标入组 90 人开始时间: 2010年8月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Alcohol intolerance 2. Symptomatic brain metastasis 3. Paralytic or mechanical bowel obstruction 4. Watery diarrhea 5. Uncontrolled ascites or pleural effusions 6. Confirmed or suspected infection 7. Severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe emphysematous) 8. Severe comorbidities (uncontrollable diabetes, heart failure with NYHA III or IV, renal failure, liver failure) 9. Pregnant woman, lactating woman 10. Sever neurologic disease 11. Grade2 or more neuropathy 12. HIV infection
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 dose-escalation study of veliparib to determine a recommended Phase 2 dose in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed); followed by a Phase 2 study to assess whether the addition of nivolumab to veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed); results in improved treatment outcomes in subjects with metastatic or advanced non-small cell lung cancer.Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)EUCTR2016-001658-16-CZAbbVie Deutschland GmbH & Co. KG174
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung CancerStage III Non-Small Cell Lung CancerMedDRA version: 19.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001659-32-GRAbbVie Deutschland GmbH & Co. KG186
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung CancerStage III Non-Small Cell Lung CancerMedDRA version: 19.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001659-32-CZAbbVie Deutschland GmbH & Co. KG186
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung CancerEUCTR2016-001659-32-HUAbbVie Deutschland GmbH & Co. KG186
进行中（未招募）
1 期
A Phase 1 dose-escalation study of veliparib to determine a recommended Phase 2 dose in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed); followed by a Phase 2 study to assess whether the addition of nivolumab to veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed); results in improved treatment outcomes in subjects with metastatic or advanced non-small cell lung cancer.EUCTR2016-001658-16-HUAbbVie Deutschland GmbH & Co. KG174